Compare · BRVE vs MRK
BRVE vs MRK
Side-by-side comparison of Braveheart Bio Inc. (BRVE) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRVE and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $327.41B, about 189.1x BRVE ($1.73B).
- Over the past year, BRVE is down 36.9% and MRK is up 39.8% - MRK leads by 76.6 points.
- MRK has been more active in the news (24 items in the past 4 weeks vs 10 for BRVE).
- MRK has more recent analyst coverage (25 ratings vs 0 for BRVE).
- Company
- Braveheart Bio Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- $1.73B
- $327.41B
- 1M return
- -8.42%
- -11.44%
- 1Y return
- -36.90%
- +39.75%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 10
- 24
- Recent ratings
- 0
- 25
Braveheart Bio Inc.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest BRVE
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
- SEC Form 10-Q filed by Braveheart Bio Inc.
- Braveheart Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
- Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
- Braveheart Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
- SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.
Latest MRK
- Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Merck & Company Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
- Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- Merck Announces First-Quarter 2027 Dividend
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis